Literature DB >> 31061144

Immunizations with Enterotoxigenic Escherichia coli Heat-Stable Toxin Conjugates Engender Toxin-Neutralizing Antibodies in Mice That Also Cross-React with Guanylin and Uroguanylin.

Yuleima Diaz1, Morten L Govasli1, Ephrem Debebe Zegeye1, Halvor Sommerfelt2,3, Hans Steinsland2,4, Pål Puntervoll5,2.   

Abstract

Infection with enterotoxigenic Escherichia coli (ETEC) is a common cause of childhood diarrhea in low- and middle-income countries, as well as of diarrhea among travelers to these countries. In children, ETEC strains secreting the heat-stable toxin (ST) are the most pathogenic, and there are ongoing efforts to develop vaccines that target ST. One important challenge for ST vaccine development is to construct immunogens that do not elicit antibodies that cross-react with guanylin and uroguanylin, which are endogenous peptides involved in regulating the activity of the guanylate cyclase-C (GC-C) receptor. We immunized mice with both human ST (STh) and porcine ST (STp) chemically coupled to bovine serum albumin, and the resulting sera neutralized the toxic activities of both STh and STp. This suggests that a vaccine based on either ST variant can confer cross-protection. However, several anti-STh and anti-STp sera cross-reacted with the endogenous peptides, suggesting that the ST sequence must be altered to reduce the risk of unwanted cross-reactivity. Epitope mapping of four monoclonal anti-STh and six anti-STp antibodies, all of which neutralized both STh and STp, revealed that most epitopes appear to have at least one amino acid residue shared with guanylin or uroguanylin. Despite this, only one monoclonal antibody displayed demonstrable cross-reactivity to the endogenous peptides, suggesting that targeted mutations of a limited number of ST residues may be sufficient to obtain a safe ST-based vaccine.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  ETEC; diarrhea; enterotoxigenic Escherichia colizzm321990; enterotoxin; epitope mapping; guanylin; heat-stable toxin; immunological cross-reaction; uroguanylin; vaccine

Mesh:

Substances:

Year:  2019        PMID: 31061144      PMCID: PMC6589059          DOI: 10.1128/IAI.00099-19

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

Review 1.  Heat-stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine target.

Authors:  Arne Taxt; Rein Aasland; Halvor Sommerfelt; James Nataro; Pål Puntervoll
Journal:  Infect Immun       Date:  2010-03-15       Impact factor: 3.441

2.  Gastrointestinal pain: unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation.

Authors:  Inmaculada Silos-Santiago; Gerhard Hannig; Helene Eutamene; Elena E Ustinova; Sylvie G Bernier; Pei Ge; Christopher Graul; Sarah Jacobson; Hong Jin; Elaine Liong; Marco M Kessler; Tammi Reza; Samuel Rivers; Courtney Shea; Boris Tchernychev; Alexander P Bryant; Caroline B Kurtz; Lionel Bueno; Michael A Pezzone; Mark G Currie
Journal:  Pain       Date:  2013-06-05       Impact factor: 6.961

Review 3.  Antiviral immune responses: triggers of or triggered by autoimmunity?

Authors:  Christian Münz; Jan D Lünemann; Meghann Teague Getts; Stephen D Miller
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

4.  Towards Rational Design of a Toxoid Vaccine against the Heat-Stable Toxin of Escherichia coli.

Authors:  Arne M Taxt; Yuleima Diaz; Rein Aasland; John D Clements; James P Nataro; Halvor Sommerfelt; Pål Puntervoll
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

Review 5.  Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon?

Authors:  Maria Vadalà; Dimitri Poddighe; Carmen Laurino; Beniamino Palmieri
Journal:  EPMA J       Date:  2017-07-20       Impact factor: 6.543

6.  Passive antibodies derived from intramuscularly immunized toxoid fusion 3xSTaN12S-dmLT protect against STa+ enterotoxigenic Escherichia coli (ETEC) diarrhea in a pig model.

Authors:  Rahul M Nandre; Qiangde Duan; Yin Wang; Weiping Zhang
Journal:  Vaccine       Date:  2016-12-22       Impact factor: 3.641

7.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

8.  Enterotoxigenic Escherichia coli heat-stable toxin and heat-labile toxin toxoid fusion 3xSTaN12S-dmLT induces neutralizing anti-STa antibodies in subcutaneously immunized mice.

Authors:  Rahul Nandre; Xiaosai Ruan; Qiangde Duan; Weiping Zhang
Journal:  FEMS Microbiol Lett       Date:  2016-11-01       Impact factor: 2.820

9.  Dose-Response Analysis Using R.

Authors:  Christian Ritz; Florent Baty; Jens C Streibig; Daniel Gerhard
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

10.  Purification and Characterization of Native and Vaccine Candidate Mutant Enterotoxigenic Escherichia coli Heat-Stable Toxins.

Authors:  Morten L Govasli; Yuleima Diaz; Ephrem Debebe Zegeye; Christine Darbakk; Arne M Taxt; Pål Puntervoll
Journal:  Toxins (Basel)       Date:  2018-07-03       Impact factor: 4.546

View more
  4 in total

1.  Vaccines against gastroenteritis, current progress and challenges.

Authors:  Hyesuk Seo; Qiangde Duan; Weiping Zhang
Journal:  Gut Microbes       Date:  2020-06-18

2.  Confronting challenges to enterotoxigenic Escherichia coli vaccine development.

Authors:  James M Fleckenstein
Journal:  Front Trop Dis       Date:  2021-09-24

3.  Vaccine Candidate Double Mutant Variants of Enterotoxigenic Escherichia coli Heat-Stable Toxin.

Authors:  Ephrem Debebe Zegeye; Yuleima Diaz; Pål Puntervoll
Journal:  Vaccines (Basel)       Date:  2022-02-04

4.  Immune Response after Skin Delivery of a Recombinant Heat-Labile Enterotoxin B Subunit of Enterotoxigenic Escherichia coli in Mice.

Authors:  Melibea Berzosa; Alzbeta Nemeskalova; Amaia Zúñiga-Ripa; Miriam Salvador-Bescós; Eneko Larrañeta; Ryan F Donnelly; Carlos Gamazo; Juan M Irache
Journal:  Pharmaceutics       Date:  2022-01-20       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.